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Poster Session II S307rapid mobilization of HSCs from niche spaces to peripheral blood.
We hypothesize that AMD3100 creates space within the endogenous
stem cell niche allowing for better engraftment of transplanted HSC
donors.
We found that subcutaneous injections of AMD3100 (5mg/kg)
into C57/BL6-Rag2 common gamma chain-deficient mice induced
mobilization of HSCs from bone marrow and absolute numbers of
HSC in bone marrow reached a nadir four hours post-AMD3100 in-
jection (20136553 vs. 37656392, p 5 0.02, n 5 4-6). AMD3100
pre-treated immunodeficient recipients were transplanted with a bo-
lus dose of 6300 MHC-mismatched AKR/j HSCs. We also per-
formed daily rounds of AMD3100 injections followed by low dose
injections of 450 HSCs over the course of 14 days for a total trans-
plant of 6300 cells. HSC bone marrow donor chimerism 12-weeks
post-transplant was not increased in the bolus-transplanted animals
(1.960.6% vs. 1.460.3%, p5 0.7, n5 5-9). Repeat-transplanted an-
imals exhibited a slight increase in engraftment; however, this in-
crease was not found to be statically significant (2.160.2% vs.
2.560.8%, p 5 0.4, n 5 4-5). These data demonstrate that while
AMD3100 is effective as a HSC mobilizer, it is not effective in
increasing engraftment potential of transplant recipients.421
USE OF UMBILICAL CORD BLOOD IN TRANSPLANTATION FOR PATIENTS
WITH MYELODYSPLASTIC SYNDROME
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Myelodysplastic Syndrome is a clonal hematological disorder
characterized by peripheral cytopenias with significant risk for pro-
gression to acute myeloid leukemia (AML). It is the most common
hematological malignancy in the elderly with 86% of all MDS diag-
noses reported in individuals over 60 years of age, according to
SEER data. While hypomethylating agents may delay disease pro-
gression and extend overall survival in low riskMDS patients, alloge-
neic hematopoietic stem cell transplant is the only potentially
curative therapy for high risk MDS. The use of umbilical cord blood
as a stem cell source forMDSpatients is attractive because of rapidity
of availability as well as the lower risk of GVHD with increasing
HLA disparity. Outcomes data is limited, but encouraging results
have been reported. This study seeks to examine transplant outcomesTable 1. Data Summary – Single and Dual Cord Blood Trans-
plants
Variable Single Cord Blood Dual Cord Blood
N 24 22
Patient Age
Mean 14.1 44.9
Conditioning Regimen
Myeloablative 21 9
Non-Myeloablative 3 13
ANC Achieved
Yes 24 (100%) 19 (86.4%)
No 0 (0%) 3 (13.6%)
Days to ANC Achieved
Mean 23.3 24.0
Acute GVHD
Yes 17 (70.8%) 4 (18.2%)
No 7 (29.2%) 6 (27.3%)
Unknown 0 (0%) 12 (54.5%)
Chronic GVHD
Yes 6 (25%) 1 (4.5%)
No 16 (66.7%) 8 (36.4%)
Unknown 2 (8.3%) 13 (59.1%)
Survival
Alive 17 (70.8%) 11 (50%)
Expired 7 (29.2%) 11 (50%)
Mean Survival (months) 23.1 11.2of MDS patients receiving umbilical cord blood units from the St.
Louis Cord Blood Bank (SLCBB).
As of September 30, 2010, the SLCBB has shipped units for 95
MDS patients, of which outcomes data is available for 46. Summary
data is provided in the table below for single and dual cord
transplants: Umbilical cord blood is a viable source of stem cells
for HSCT in MDS patients. More data will be required to examine
a possible risk of increased graft vs. host disease with this population.422
KILLER-IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) GENE POLYMOR-
PHISM AND BKV ASSOCIATED HEMORRHAGIC CYSTITIS IN HEMATOPOI-
ETIC STEM CELL TRANSPLANT RECIPIENTS
Askar, M., Mossad, S., Zhang, A., Rybicki, L., Thomas, D., Tench, S.,
Copelan, E., Bolwell, B., Sobecks, R. Cleveland Clinic
Hemorrhagic cystitis (HC) is the most prevalent complication of
BK viruria after allogeneic hematopoietic stem cell transplantation
(HSCT) and is associated with significant morbidity and mortality.
However, why 40–50% of HSCT recipients with persistent viruria
never developHC remains unclear. Killer-immunoglobulin-like Re-
ceptor (KIR) gene polymorphism has been implicated in influencing
clinical outcomes of a number of viruses such as CMV, Hepatitis C,
and HIV.
Objective: To determine whether KIR gene polymorphisms has
a potential role in the development of BKV associated HC after
allogeneic HSCT.
Methods: We performed a retrospective 1:2 matched case-control
study of allogeneic HSCT recipients who underwent transplant at
our institution from 2000-2010. We performed KIR genotyping
for 32 cases with BKV associated HC and 64 matched controls with-
out HC. Two controls were selected for each case, and matched for
disease, preparative regimen, and development of acute GvHD prior
to HC. Recipient KIR genotyping was determined by PCR-rSSOP
(Luminex, One Lambda). Recipient KIR genotype and haplotypes
were assigned as described previously (Middleton andGonzelez, Im-
munology, 2010). The donor’s human leukocyte antigen (HLA) typ-
ing was reviewed from patient charts for determination of KIR
ligands. Conditional logistic regression analysis was used to assess
the association of KIR gene polymorphism and BKV associated
HC. Stepwise analysis using a variable entry criterion of P\ 0.10
and a variable retention criterion of P \ 0.05 was used to assess
multivariable risk factors.
Results:No significant association was identified at the 5% level of
significance between the development of HC and KIR genotypes,
Haplotypes (AA vs. Bx), number of activating receptors, presence
of any particular activating or inhibitory KIRs, or presence of any
cognate HLA ligands.
Conclusion: In contrast to the reported associations between KIR
gene polymorphism and different outcomes of other viruses, our
study does not support a role for KIR gene polymorphism in the
development of BKV associated HC.
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WHY WORK-UP REQUESTS FOR HSCT DONORS FAIL – REASONS AND
WAYS TO IMPROVE FROM A DONOR CENTER PERSPECTIVE
Mengling, T.1, Cotta, L.1, Schmidt, A.H.1, Ehninger, G.2 1DKMS
German Bone Marrow Donor Center, Tuebingen, Germany; 2University
Hospital Carl Gustav Carus, Dresden, Germany
Since 1992, DKMS German Bone Marrow Center has processed
28,672 work-up requests for hematopoietic stem cell donations.
4,328 requests (15.1%) were cancelled by the transplant centers for
patient-related reasons. Of the remaining, 22,840 (93.8%) requests
were successfully completed by collection and transplantation of a vi-
able stem cell product.
Since every work-up is a time and resource intensive process, it is
crucial to minimize the number of futile requests. Therefore, we
have assessed medical and non-medical conditions leading to donor
deferral or temporary unavailability, and identified donor subgroups
more likely to cancel their willingness late in the donor search pro-
cess. Due to the additional costs and loss of time, donors who did
